Selective androgen receptor modulators

Details Selective androgen receptor modulators Selective androgen receptor modulators

2009-02-19

2011-11-29

Anderson, Rebecca (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C548S143000

Reexamination Certificate

active

08067448

ABSTRACT:
This invention provides compounds of formulas I, Ia, Ib, Ic, Id, Ie, and or salts thereof, pharmaceutical compositions comprising a compound of formulas I, Ia, Ib, Ic, Id, Ie, and a pharmaceutically acceptable excipient, methods of modulating the androgen receptor, methods of treating diseases beneficially treated by an androgen receptor modulator (e.g., sarcopenia, prostate cancer, contraception, type 2 diabetes related disorders or diseases, anemia, depression, and renal disease) and processes for making compounds of formulas I, Ia, Ib, Ic, Id, Ie, and intermediates useful in the preparation of same.

REFERENCES:
patent: 5411981 (1995-05-01), Gaillard-Kelly et al.
patent: 6960474 (2005-11-01), Salvati et al.
patent: 2005/0182105 (2005-08-01), Nirschl et al.
patent: 2005/0250749 (2005-11-01), Labrie et al.
patent: 2005/0261303 (2005-11-01), Taniguchi et al.
patent: 2006/0106067 (2006-05-01), Shiraishi et al.
patent: 2006/0142387 (2006-06-01), Cadilla et al.
patent: 2006/0148893 (2006-07-01), Blanc et al.
patent: 2006/0211756 (2006-09-01), Zhang et al.
patent: 2006/0287327 (2006-12-01), Labrie et al.
patent: 2007/0088039 (2007-04-01), Balog et al.
patent: 2007/0281906 (2007-12-01), Dalton et al.
patent: 2008/0057068 (2008-03-01), Dalton et al.
patent: 2009/0042967 (2009-02-01), Hasuoka
patent: 2009/0264534 (2009-10-01), Dalton et al.
patent: 2010/0041721 (2010-02-01), Miller
patent: 0 580 459 (2001-03-01), None
patent: 01-261381 (1989-10-01), None
patent: WO 96/41793 (1996-12-01), None
patent: WO 97/49709 (1997-12-01), None
patent: WO 02/16310 (2002-02-01), None
patent: WO 03/011824 (2003-02-01), None
patent: WO 03/068217 (2003-08-01), None
patent: WO 03/096980 (2003-11-01), None
patent: WO 2004/041277 (2004-05-01), None
patent: WO 2004/041782 (2004-05-01), None
patent: WO 2004/045518 (2004-06-01), None
patent: WO 2004/080377 (2004-09-01), None
patent: WO 2004/110978 (2004-12-01), None
patent: WO 2005/000309 (2005-01-01), None
patent: WO 2005/000794 (2005-01-01), None
patent: WO 2005/000795 (2005-01-01), None
patent: WO 2005/040136 (2005-05-01), None
patent: WO 2005/042464 (2005-05-01), None
patent: WO 2005/049574 (2005-06-01), None
patent: WO 2005/049580 (2005-06-01), None
patent: WO 2005/060956 (2005-07-01), None
patent: WO 2005/077925 (2005-08-01), None
patent: WO 2005/085185 (2005-09-01), None
patent: WO 2005/086735 (2005-09-01), None
patent: WO 2005/087232 (2005-09-01), None
patent: WO 2005/089118 (2005-09-01), None
patent: WO 2005/090282 (2005-09-01), None
patent: WO 2005/090328 (2005-09-01), None
patent: WO 2005/094810 (2005-10-01), None
patent: WO 2005/099707 (2005-10-01), None
patent: WO 2005/102998 (2005-11-01), None
patent: WO 2005/108351 (2005-11-01), None
patent: WO 2005/111028 (2005-11-01), None
patent: WO 2005/115361 (2005-12-01), None
patent: WO 2005/116001 (2005-12-01), None
patent: WO 2005/120483 (2005-12-01), None
patent: WO 2006/039243 (2006-04-01), None
patent: WO 2006/044707 (2006-04-01), None
patent: WO 2006/055184 (2006-05-01), None
patent: WO 2006/060108 (2006-06-01), None
patent: WO 2006/076317 (2006-07-01), None
patent: WO 2006/113552 (2006-10-01), None
patent: WO 2006/124447 (2006-11-01), None
patent: WO 2006/133216 (2006-12-01), None
patent: WO 2007/002181 (2007-01-01), None
patent: WO 2007/005887 (2007-01-01), None
patent: WO 2007/015567 (2007-02-01), None
patent: WO 2007/034846 (2007-03-01), None
patent: WO 2007/067490 (2007-06-01), None
patent: WO 2007/087518 (2007-08-01), None
patent: WO 2007/099200 (2007-09-01), None
patent: WO 2008/008433 (2008-01-01), None
patent: WO 2008/011072 (2008-01-01), None
patent: WO 2008/011073 (2008-01-01), None
patent: WO 2008/024456 (2008-02-01), None
patent: WO 2008/042571 (2008-04-01), None
patent: WO 2008/044033 (2008-04-01), None
patent: WO 2008/063867 (2008-05-01), None
patent: WO 2008/121602 (2008-10-01), None
patent: WO 2008/124000 (2008-10-01), None
patent: WO 2008/124922 (2008-10-01), None
patent: WO 2008/127717 (2008-10-01), None
patent: WO 2008/128100 (2008-10-01), None
patent: WO 2009/081197 (2009-07-01), None
patent: WO 2009/082437 (2009-07-01), None
patent: WO 2009/105214 (2009-08-01), None
patent: WO 2009/133861 (2009-11-01), None
patent: WO 2009/140448 (2009-11-01), None
Acevedo, S., et al., “Selective Androgen Receptor Modulators Antagonize Apolipoprotein E4-Induced Cognitive Impairments,”Letters in Drug Design&Discovery, 5: 271-276 (2008).
Allan G. F., et al., “A Selective Androgen Receptor Modulator with Minimal Prostate Hypertrophic Activity Enhances Lean Body Mass in Male Rats and Stimulates Sexual Behavior in Female Rats,”Endocr., 32: 41-51 (2007).
Allan, G., et al., “A Selective Androgen Receptor Modulator that Reduces Prostate Tumor Size and Prevents Orchidectomy-Induced Bone Loss in Rats,”Journal of Steroid Biochemistry&Molecular Biology, 103: 76-83 (2007).
Bohl, C.E., et al., “Structural Basis for Accommodation of Nonsteroidal Ligands in the Androgen Receptors,”The Journal of Biological Chemistry, 280 (45): 37747-37754 (Nov. 11, 2005).
Bohl, C. E., “Structural Basis for Antagonism and Resistance of Bicalutamide in Prostate Cancer,”PNAS, 102 (17): 6201-6206 (2005).
Cantin, L., et al., “Structural Characterization of the Human Androgen Receptor Ligand-Binding Domain Complexed with EM5744, a Rationally Designed Steroidal Ligand Bearing a Bulky Chain Directed Toward Helix 12,”Journal of Biological Chemistry, 282 (42): 30910-30919 (Oct. 19, 2007).
Gao, W., et al., “Ockham's Razor and Selective Androgen Receptor Modulators (SARMs): Are we Overlooking the Role of 5α-Reductase?”,Molecular Interventions, 7: 10-13 (Feb. 2007).
Gao, W., et al., “Expanding the Therapeutic use of Androgens via Selective Androgen Receptor Modulators (SARMs),”Drug Discovery Today, 12: 241-248 (Mar. 2007).
Gao, W., et al., “Selective Androgen Receptor Modulator (SARM) Treatment Improves Muscle Strength,”Endocrinology, doi:10.1210/en.2005-0572, pp. 1-37 (Aug. 11, 2005).
Gao, W., et al., “Comparison of the Pharmacological Effects of a Novel Selective Androgen Receptor Modulator, the 5α-Reductase Inhibitor Finasteride, and the Antiandrogen Hydroxyflutamide in Intact Rats: New Approach for Benign Prostate Hyperplasia,”Endocrinology, 145 (12): 5420-5428 (Dec. 2004).
Gao, W., et al., “Selective Androgen Receptor Modulator Treatment Improves Muscle Strength and Body Composition and Prevents Bone Loss in Orchidectomized Rats,”Endocrinology, 146 (11): 4887-4897 (Nov. 2005).
Hamann, L G., “Discovery and Preclinical Profile of a Highly Potent and Muscle Selective Androgen Receptor Modulator (SARM),” 227thNational Meeting of the American Chemical Society Medicinal Chemistry Division, Mar. 28, 2004, Anaheim, CA.
Hamann, L.G., et al., “Tandem Optimization of Target Activity and Elimination of Mutagenic Potential in a Potent Series ofN-aryl Bicyclic Hydantoin-Based Selective Androgen Receptor Modulators,”Bioorganic&Medicinal Chemistry Letters, 17: 1860-1864 (2007).
Hanada, K., et al. “Bone Anabolic Effects of S-40503, a Novel Nonsteroidal Selective Androgen Receptor Modulator (SARM), in Rat Models of Osteoporosis,”Biol. Pharm. Bull., 26(11): 1563- 1569 (Nov. 2003).
Higuchi, R. I., et al., “Novel Series of Potent, Nonsteroidal, Selective Androgen Receptor Modulators Based on 7 H-[1,4]Oxazino[3,2-g]quinolin-7-ones,”J. Med. Chem., 50(10): 2486-2496 (2007).
Higuchi, R. I., et al.,“Novel Series of Potent, Nonsteroidal, Selectve Androgen Receptor Modulators Based on 7H[1,4]Oxazino[3,2-g]quinolin-7-ones,”Journal of Medicinal Chemistry, pp. A-K (Apr. 17, 2007).
Hwang, D. J., et al., “Arylisothiocyanato Selective Androgen Receptor Modulators (SARMs) for Prostate Cancer,”Bioorganic&Medicinal Chemistry, 14: 6525-6538 (2006).
Kemppainen, J. A., et al., “Distinguishing Androgen Receptor Agonists and Antagonists: Distinct Mechanisms of Activation by Medroxyprogesterone Acetate

Affiliated with

Also associated with

Rating

Selective androgen receptor modulators does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Selective androgen receptor modulators, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Selective androgen receptor modulators will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4279268